Besides, human NSCLC cells, including tumor cell lines and primary tumor cells from clinical patients, can efficiently drive metabolic adaptation of human CD4 + T cells, directing differentiation of regulatory T cells while suppressing effector T cells [46]. The gene discussed is CD4; the disease is neoplasm.